MYC expression has limited utility in the distinction of undifferentiated radiation‐associated sarcomas from sporadic sarcomas and sarcomatoid carcinoma. Issue 4 (28th July 2020)

• Record Type: Journal Article
• Authors: Mito, Jeffrey K; Qian, Xiaohua; Jo, Vickie Y; Doyle, Leona A
• Is Part Of: Histopathology. Volume 77:Issue 4(2021)
• Page Start: 667
• Page End: 672
• Publication Date: 2020-07-28
• Subjects: carcinoma -- immunohistochemistry -- MYC -- radiation -- sarcoma; Histology, Pathological -- Periodicals; 611.018
• DOI: 10.1111/his.14168
• Languages: English
• ISSNs: 0309-0167

Abstract

Abstract : Aims: MYC is a proto‐oncogene that is frequently dysregulated in various malignancies, through translocation or amplification. Radiation‐associated angiosarcoma frequently shows MYC amplification, and immunohistochemical expression has been shown to be a reliable surrogate marker for amplification, but less is known about MYC expression in other sarcoma types, despite reports of MYC amplification in some undifferentiated/unclassified radiation‐associated sarcomas (RASs). Distinguishing putative RAS from non‐radiation‐associated sarcoma or sarcomatoid carcinoma can be difficult. The aim of this study was to determine the prevalence and potential diagnostic utility of MYC in this context, by evaluating MYC expression in a cohort of RASs, non‐radiation‐associated sarcomas, and sarcomatoid carcinomas. Methods and results: Three hundred and eighty‐five neoplasms were evaluated, including 81 RASs (18 angiosarcomas; 57 undifferentiated sarcomas; three leiomyosarcomas; and three malignant peripheral nerve sheath tumours), 267 non‐radiation‐associated sarcomas, and 37 sarcomatoid carcinomas. Immunohistochemistry was performed with a monoclonal anti‐MYC antibody. Staining in tumour cells was scored on the basis of extent (focal, 1–4%; multifocal, 5–49%; and diffuse, ≥50%) and intensity (strong, moderate, and weak). One hundred percent of radiation‐associated angiosarcomas expressed MYC diffusely. Expression was infrequent among other types of RAS (9.5%), and the frequency was similar to that in non‐radiation‐associated sarcomas (9.7%). MYC expression was more common in sarcomatoid carcinomas, occurring in 43%. The extent and intensity of staining were variable in all groups. Conclusion: MYC expression is infrequent among RASs other than angiosarcoma, and has a similar prevalence in sporadic sarcomas. Given the frequency of expression in sarcomatoid carcinomas, MYC expression outside the context of radiation‐associated angiosarcoma is of limited diagnostic utility, and should be interpreted with caution after exclusion of sarcomatoid carcinoma where relevant.